IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P

May 25, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.

[mfn_before_post]

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.

The scientific paper describes the prospective, single-center, randomized, double-blind, placebo-controlled phase I, first-in-human (FIH) study with mesdopetam. The study evaluated the safety, tolerability, and pharmacokinetics of escalating single and multiple doses of mesdopetam. It was concluded that mesdopetam was safe and well-tolerated in healthy male volunteers. Pharmacokinetic analysis indicated rapid absorption and dose-linear pharmacokinetics of mesdopetam upon single and repeated dosing. The pharmacokinetics of mesdopetam supports twice-daily use in patients.

“The published paper for mesdopetam’s Phase I study strengthens the growing scientific evidence of the drug candidate’s significant potential in Parkinson’s. The acceptance in PR&P enables our study results to reach a wide audience” said Susanna Waters, M.D., Ph.D, Director of Biology & Biostatistics at IRLAB.

The journal Pharmacology Research & Perspectives (PR&P) is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. The journal’s topics of interest includes new pharmacological hypotheses, mechanism of action, drug target identification and preclinical and clinical validation, drug discovery reviews, frontiers in translational medicine, and replication studies.

Publication: Sjöberg F, Waters S, Löfberg B, Sonesson C, Waters N, Tedroff J. A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. Pharmacol Res Perspect. 2021;9:e00792. https://doi.org/10.1002/prp2.792.

For more information

Susanna Waters, Director of Biology & Biostatistics
Phone: +46 730 75 77 02
E-mail: susanna.waters@irlab.se

Joakim Tedroff, CMO
Phone: +46 70 760 16 91
E-mail: joakim.tedroff@irlab.se  

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.

[mfn_after_post]

Documents & Links